Agenus Inc. (AGEN)

US — Healthcare Sector
Peers: INO  ABOS  IRD  SEER  ZNTL  HURA  PLRX  VTGN  FATE  TTRX 

Automate Your Wheel Strategy on AGEN

With Tiblio's Option Bot, you can configure your own wheel strategy including AGEN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol AGEN
  • Rev/Share 3.3503
  • Book/Share -8.8085
  • PB -0.3571
  • Debt/Equity -0.167
  • CurrentRatio 0.4665
  • ROIC 1.4586

 

  • MktCap 104405481.0
  • FreeCF/Share -2.8009
  • PFCF -1.169
  • PE -2.7837
  • Debt/Assets 0.1957
  • DivYield 0
  • ROE 0.1085

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade AGEN H.C. Wainwright Neutral Buy -- $25 June 4, 2025

News

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting
AGEN
Published: February 12, 2025 by: Business Wire
Sentiment: Neutral

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. An oral presentation will highlight interim data from the ongoing Phase 2 study of botensilimab and balstilimab (BOT/BAL) in combination with MiNK Therapeutics' iNKT cell therapy, AgenT-797,.

Read More
image for news Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

About Agenus Inc. (AGEN)

  • IPO Date 2000-02-08
  • Website https://www.agenusbio.com
  • Industry Biotechnology
  • CEO Garo H. Armen
  • Employees 316
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.